{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T09:33:07Z","timestamp":1778923987696,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T00:00:00Z","timestamp":1569456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Surg Int"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00383-019-04563-5","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T20:33:53Z","timestamp":1569530033000},"page":"1369-1378","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Epidermal growth factor receptor\/heme oxygenase-1 axis is involved in chemoresistance to cisplatin and pirarubicin in HepG2 cell lines and hepatoblastoma specimens"],"prefix":"10.1007","volume":"35","author":[{"given":"Takashi","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunobu","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mami","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,26]]},"reference":[{"issue":"1","key":"4563_CR1","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cncr.20357","volume":"101","author":"G Latini","year":"2004","unstructured":"Latini G, Gallo F, De Felice C (2004) Birth characteristics and hepatoblastoma risk in young children. Cancer 101(1):210","journal-title":"Cancer"},{"issue":"3","key":"4563_CR2","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.suronc.2007.07.002","volume":"16","author":"RL Meyers","year":"2007","unstructured":"Meyers RL (2007) Tumors of the liver in children. Surg Oncol 16(3):195\u2013203","journal-title":"Surg Oncol"},{"issue":"3","key":"4563_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/MOP.0000000000000081","volume":"26","author":"N Kremer","year":"2014","unstructured":"Kremer N, Walther AE, Tiao GM (2014) Management of hepatoblastoma: an update. Curr Opin Pediatr 26(3):362\u2013369","journal-title":"Curr Opin Pediatr"},{"issue":"1","key":"4563_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00383-010-2708-0","volume":"27","author":"T Hishiki","year":"2011","unstructured":"Hishiki T, Matsunaga T, Sasaki F, Yano M, Ida K, Horie H, Kondo S, Watanabe K, Oue T, Tajiri T, Kamimatsuse A, Ohnuma N, Hiyama E (2011) Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT. Pediatr Surg Int 27(1):1\u20138","journal-title":"Pediatr Surg Int"},{"issue":"18","key":"4563_CR5","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1200\/JCO.2005.02.6013","volume":"24","author":"MH Malogolowkin","year":"2006","unstructured":"Malogolowkin MH, Katzenstein H, Krailo MD, Chen Z, Bowman L, Reynolds M, Finegold M, Greffe B, Rowland J, Newman K, Womer RB, London WB, Castleberry RP (2006) Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol 24(18):2879\u20132884","journal-title":"J Clin Oncol"},{"issue":"9","key":"4563_CR6","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","volume":"14","author":"J Zsiros","year":"2013","unstructured":"Zsiros J, Brugieres L, Brock P, Roebuck D, Maibach R, Zimmermann A, Childs M, Pariente D, Laithier V, Otte JB, Branchereau S, Aronson D, Rangaswami A, Ronghe M, Casanova M, Sullivan M, Morland B, Czauderna P, Perilongo G, International Childhood Liver Tumours Strategy G (2013) Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 14(9):834\u2013842","journal-title":"Lancet Oncol"},{"issue":"10","key":"4563_CR7","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s00383-013-3399-0","volume":"29","author":"E Hiyama","year":"2013","unstructured":"Hiyama E, Ueda Y, Onitake Y, Kurihara S, Watanabe K, Hishiki T, Tajiri T, Ida K, Yano M, Kondo S, Oue T, Japanese Study Group for Pediatric Liver T (2013) A cisplatin plus pirarubicin-based JPLT2 chemotherapy for hepatoblastoma: experience and future of the Japanese Study Group for Pediatric Liver Tumor (JPLT). Pediatr Surg Int 29(10):1071\u20131075","journal-title":"Pediatr Surg Int"},{"issue":"5","key":"4563_CR8","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/pbc.24219","volume":"59","author":"AD Trobaugh-Lotrario","year":"2012","unstructured":"Trobaugh-Lotrario AD, Katzenstein HM (2012) Chemotherapeutic approaches for newly diagnosed hepatoblastoma: past, present, and future strategies. Pediatr Blood Cancer 59(5):809\u2013812","journal-title":"Pediatr Blood Cancer"},{"key":"4563_CR9","doi-asserted-by":"publisher","first-page":"1958174","DOI":"10.1155\/2016\/1958174","volume":"2016","author":"AL Furfaro","year":"2016","unstructured":"Furfaro AL, Traverso N, Domenicotti C, Piras S, Moretta L, Marinari UM, Pronzato MA, Nitti M (2016) The Nrf2\/HO-1 axis in cancer cell growth and chemoresistance. Oxid Med Cell Longev 2016:1958174","journal-title":"Oxid Med Cell Longev"},{"issue":"10","key":"4563_CR10","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1016\/j.humpath.2009.07.003","volume":"40","author":"D Lopez-Terrada","year":"2009","unstructured":"Lopez-Terrada D, Cheung SW, Finegold MJ, Knowles BB (2009) Hep G2 is a hepatoblastoma-derived cell line. Hum Pathol 40(10):1512\u20131515","journal-title":"Hum Pathol"},{"issue":"1","key":"4563_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3892\/ol.2016.5416","volume":"13","author":"T Matsuo","year":"2017","unstructured":"Matsuo T, Miyata Y, Mitsunari K, Yasuda T, Ohba K, Sakai H (2017) Pathological significance and prognostic implications of heme oxygenase 1 expression in non-muscle-invasive bladder cancer: Correlation with cell proliferation, angiogenesis, lymphangiogenesis and expression of VEGFs and COX-2. Oncol Lett 13(1):275\u2013280","journal-title":"Oncol Lett"},{"issue":"2\u20133","key":"4563_CR12","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/0014-2999(93)90951-D","volume":"234","author":"K Temma","year":"1993","unstructured":"Temma K, Akera T, Chugun A, Kondo H, Hagane K, Hirano S (1993) Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart. Eur J Pharmacol 234(2\u20133):173\u2013181","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"4563_CR13","first-page":"153","volume":"20","author":"S Hirano","year":"1994","unstructured":"Hirano S, Wakazono K, Agata N, Iguchi H, Tone H (1994) Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat. Drugs Exp Clin Res 20(4):153\u2013160","journal-title":"Drugs Exp Clin Res"},{"key":"4563_CR14","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.freeradbiomed.2013.10.819","volume":"67","author":"HK Na","year":"2014","unstructured":"Na HK, Surh YJ (2014) Oncogenic potential of Nrf2 and its principal target protein heme oxygenase-1. Free Radic Biol Med 67:353\u2013365","journal-title":"Free Radic Biol Med"},{"issue":"12","key":"4563_CR15","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1016\/j.bcp.2010.07.014","volume":"80","author":"A Paine","year":"2010","unstructured":"Paine A, Eiz-Vesper B, Blasczyk R, Immenschuh S (2010) Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential. Biochem Pharmacol 80(12):1895\u20131903","journal-title":"Biochem Pharmacol"},{"issue":"5\u20136","key":"4563_CR16","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0006-2952(02)01137-1","volume":"64","author":"ED Owuor","year":"2002","unstructured":"Owuor ED, Kong AN (2002) Antioxidants and oxidants regulated signal transduction pathways. Biochem Pharmacol 64(5\u20136):765\u2013770","journal-title":"Biochem Pharmacol"},{"issue":"5205","key":"4563_CR17","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1126\/science.7892601","volume":"267","author":"A Levitzki","year":"1995","unstructured":"Levitzki A, Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267(5205):1782\u20131788","journal-title":"Science"},{"issue":"1","key":"4563_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.lungcan.2009.03.015","volume":"67","author":"H Kuroda","year":"2010","unstructured":"Kuroda H, Takeno M, Murakami S, Miyazawa N, Kaneko T, Ishigatsubo Y (2010) Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells. Lung Cancer 67(1):31\u201336","journal-title":"Lung Cancer"},{"issue":"30","key":"4563_CR19","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.1016\/j.febslet.2008.11.010","volume":"582","author":"T Yoshida","year":"2008","unstructured":"Yoshida T, Okamoto I, Iwasa T, Fukuoka M, Nakagawa K (2008) The anti-EGFR monoclonal antibody blocks cisplatin-induced activation of EGFR signaling mediated by HB-EGF. FEBS Lett 582(30):4125\u20134130","journal-title":"FEBS Lett"},{"issue":"9742","key":"4563_CR20","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, To GATI (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687\u2013697","journal-title":"Lancet"},{"issue":"11","key":"4563_CR21","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1093\/annonc\/mdw323","volume":"27","author":"M Ikeda","year":"2016","unstructured":"Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T (2016) Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. Ann Oncol 27(11):2090\u20132096","journal-title":"Ann Oncol"},{"issue":"1","key":"4563_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","volume":"17","author":"A du Bois","year":"2016","unstructured":"du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, Denison U, Vergote I, Del Campo JM, Ottevanger P, Heubner M, Minarik T, Sevin E, de Gregorio N, Bidzinski M, Pfisterer J, Malander S, Hilpert F, Mirza MR, Scambia G, Meier W, Nicoletto MO, Bjorge L, Lortholary A, Sailer MO, Merger M, Harter P, Consortium AGOSGlGCIENoGOTGI (2016) Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 17(1):78\u201389","journal-title":"Lancet Oncol"},{"issue":"6","key":"4563_CR23","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1007\/s10637-012-9792-z","volume":"30","author":"IG Hwang","year":"2012","unstructured":"Hwang IG, Jang JS, Oh SY, Lee S, Kwon HC, Lee GW, Go S, Kang MH, Cha YJ, Kang JH (2012) A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer. Invest New Drugs 30(6):2371\u20132376","journal-title":"Invest New Drugs"},{"issue":"8","key":"4563_CR24","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1002\/cncr.28471","volume":"120","author":"A Nogueira-Rodrigues","year":"2014","unstructured":"Nogueira-Rodrigues A, Moralez G, Grazziotin R, Carmo CC, Small IA, Alves FV, Mamede M, Erlich F, Viegas C, Triginelli SA, Ferreira CG (2014) Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer. Cancer 120(8):1187\u20131193","journal-title":"Cancer"}],"container-title":["Pediatric Surgery International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00383-019-04563-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00383-019-04563-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00383-019-04563-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,24]],"date-time":"2020-09-24T23:50:55Z","timestamp":1600991455000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00383-019-04563-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,26]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["4563"],"URL":"https:\/\/doi.org\/10.1007\/s00383-019-04563-5","relation":{},"ISSN":["0179-0358","1437-9813"],"issn-type":[{"value":"0179-0358","type":"print"},{"value":"1437-9813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,26]]},"assertion":[{"value":"12 September 2019","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}